Background: The association of infliximab [IFX] trough levels with clinical and endoscopic outcomes in inflammatory bowel disease is well established. However, there is scarce data regarding the association of perianal fistula response with IFX. The aim of this study was to establish whether early induction infliximab levels and anti-infliximab antibodies [ATIs] are associated with perianal fistula response. Methods: Consecutive CD patients with perianal fistulae that were treated with IFX between 2008 and 2016 were included in the study. Response was defined as cessation or significant improvement of fistula drainage. Patients with unavailable IFX level or ATI measurements and/or missing clinical follow-up at Week 14 were excluded. Results: A total of 36 patients with perianal fistulae were included; 25/36 [69.4%] responded to treatment by Week 14. The median induction IFX levels at Weeks 2, 6 and 14 in the responders group at Week 14 were higher compared with those of the non-responders group [20/5.6 µg/mL, P = 0.0001; 13.3/2.55 µg/mL P = 0.0001; 4.1/0.14 µg/mL, P = 0.01]. On multivariate analysis, IFX leve at Weeks 2 and 6 were significantly associated with fistula response at Weeks 14 and 30. IFX drug levels of 9.25 µg/mL at Week 2 and 7.25 µg/mL at Week 6 were the best predictors of fistula response. Conclusion: High IFX trough levels during induction are associated with favorable fistula response to anti-TNF treatment. If validated in a larger prospective study, our findings may help guide anti-TNF treatment in patients with perianal CD, and suggest serum level-guided treatment escalation in non-responders or prompt changing of biologic treatment in non-responders.
Introduction
Perianal fistulae occur in 17-43% of patients with Crohn's disease [CD] . 1 Management of fistulae involves drainage, seton insertion, antibiotics and anti-TNF treatment with or without concomitant immunomodulators. [2] [3] [4] The pivotal study that evaluated the efficacy of infliximab [IFX] for treatment of perianal fistulae demonstrated that 68% of patients had a significant reduction in the number of draining fistulae. The response was quite quick, with a median time to onset of response of 2 weeks. 1 The ACCENT II trial demonstrated that maintaining remission with IFX in responders at Week 14 was superior to the results for placebo [36% vs. 19%, P = 0.009]. Thirty-six percent of patients achieved complete cessation of drainage at Week 54. 4 Continued IFX treatment was relatively ineffective in patients who did not respond to IFX within 14 weeks [16% vs. 21% in the placebo group and IFX group respectively, P = 0.6]. 4 A retrospective study that examined the long-term efficacy of IFX demonstrated that the cumulative probability of clinical fistula closure at 1 year from the first IFX infusion was 33%. 3 Factors that favoured fistula closure were ileocolonic disease, use of concomitant immunosuppressants, and duration of seton drainage. 3 Recent studies have shown correlation between anti-TNF drug levels, anti-infliximab antibody [ATI] levels, and clinical remission and mucosal healing. [5] [6] [7] [8] Mucosal healing improves incrementally with increasing drug levels. IFX levels above 5 mg/mL identified patients with mucosal healing with a specificity of 85%. 8 However, evidence regarding the association of perianal fistula response and IFX/anti-IFX antibody levels is scarce.
The aims of the present study were to establish whether IFX trough levels are associated with perianal fistula response.
Patients and methods
This was a retrospective observational cohort study in two referral centers. Consecutive CD patients with active perianal fistulae treated with IFX by the Department of Gastroenterology at Sheba Medical Center and Rambam Health Care Campus between the years 2008 and 2016 were included in the study.
The main objective was to evaluate the correlation of IFX and ATI levels at Weeks 2, 6 and 14 with the medical response to perianal fistula at Week 14, defined as decrease or cessation in fistula drainage as reported by the patient and validated by the treating physician. Secondary aims included evaluation of correlation of IFX and ATI levels with fistula closure [ IFX was administered at a standard dose of 5 mg/kg at Weeks 0, 2 and 6, and every 8 weeks after that. No dose or schedule modification was undertaken during the induction phase.
Disease classification was defined according to the Montreal classification 9 at diagnosis. Perianal fistulae were characterized using the Parks classification 10 and classified as 'simple' or 'complex'. Patients with available clinical follow-up at Week 14 and at least one serum sample of IFX levels and ATI measurements at Weeks 2, 6 and 14 were included. Follow-up duration was defined as time from the first infliximab infusion to the last follow-up visit. Levels of IFX and ATIs were evaluated in each hospital using a previously described capture enzyme-linked immunosorbent assay [ELISA] . 12 IFX levels were reported as a continuous variable; when IFX levels were above the maximal quantification level, they were assumed to be 20 µg/mL for calculation purposes. 
Statistical analysis

Results
Patient characteristics
A total of 36 CD patients with perianal fistulae treated with IFX were included. Patient baseline characteristics are listed in Table 1 vs. 0.14 µg/mL [0.01-2.3], P = 0.01, respectively) [ Figure 1A and Table 3 ]. On multivariate analysis, the IFX levels at Weeks 2 and 6 were independently associated with fistula response at Week 14 [ Table 4 ]. The area under the curve [AUC] for association of IFX level at Week 2 with fistula improvement at Week 14 was 0.94, P = 0.0001. An IFX drug level of 9.25 µg/mL predicted fistula response at Week 14 with a sensitivity of 89% and a specificity of 90% [ Figure 2 ]. The AUC for association of IFX level at Week 6 with fistula improvement at Week 14 was 0.9, P = 0.001. An IFX drug level of 7.25 µg/ mL at Week 6 was associated with fistula improvement at Week 14 with a sensitivity of 80% and a specificity of 83% [ Figure 2 and Table 3 
Correlation between IFX levels, ATIs and fistula response at Week 30
Patients who responded at Week 30 had higher IFX levels at Weeks 2, 6 and 14 [ Figure 1B ]. Table 7 ]. The AUC for association of IFX level at Week 2 and fistula response at Week 30 was 0.9, P = 0.0001. An IFX drug level of 9.25 µg/mL predicted a response at Week 30 with a sensitivity of 82% and a specificity of 94% [ Figure 3 ]. The AUC for association of IFX level at Week 6 and fistula improvement at Week 30 was 0.85, P = 0.002. An IFX drug level of 8.6µg/mL predicted response at Week 30 with a sensitivity of 83% and a specificity of 70 % [ Figure 3 and Table 6 ]. Prevalence of ATIs was similar in responders and non-responders [ Table 5 ].
Fistula closure
Fistula closure was reported in 17 patients [47.2%] at the end of follow-up, and in 9 of these the fistula closed by the end of the first year. Sixteen of the seventeen patients were from the initial responders 
Imaging evaluation
Initial imaging evaluation of perianal disease was performed using pelvic MRI in 17/36 [47%] of patients. Twelve of thirty-six patients [33%] underwent TRUS. Repeated imaging was available in only 10/36 patients, in 7 of the 10 due to active perianal disease. The other 3 patients underwent pelvic imaging to confirm fistula closure.
One patient had a complete fistula closure, and two had insignificant residual disease [ Figure 4 ].
Discussion
To the best of our knowledge, this is the first study to evaluate the association of IFX drug levels with perianal fistula response. Our findings suggest that early IFX drug levels during the induction phase predict fistula improvement at Weeks 14 and 30. The role of IFX in the treatment of CD and particularly perianal fistula is well established. [1] [2] [3] [4] Present et al. 1 demonstrated the efficacy of IFX in induction of remission of perianal fistulae. Subsequent retrospective and open-label series confirm the efficacy of IFX in the treatment of perianal CD. 2 The ACCENT II study demonstrated the efficacy of IFX in maintaining this response. 4 Using drug level monitoring for guiding treatment decisions can improve the efficacy of anti-TNF treatment by proper dose adjustment and/or timely medication switch when necessary. 13 A post hoc analysis of the ACCENT I trial, in which response of inflammatory CD was evaluated, demonstrated that the median drug levels of IFX were higher in the responding versus non responding group at Weeks 6 and 14 [12.9 µg/mL vs. 8.8 µg/mL, P = 0.0135 and 4.0 µg/mL vs. 1.9 µg/mL, P = 0.033, respectively]. 14 The association of induction IFX levels and clinical response was recently reported in UC patients. 15 The median IFX levels at Weeks 2, 6 and 14 were higher in the short-term mucosal healing group [22.9 µg/mL, 17.6 µg/mL and 7.4 µg/mL, respectively], similar to our findings. 15 The effect of anti-TNFs on mucosal healing was also associated with higher trough levels; 90% of the patients who achieved mucosal healing had IFX trough levels >8 µg/mL. 8 Yarur et al. demonstrated that an IFX drug level of >8.3 µg/mL was highly associated with mucosal healing. 7 Our findings suggest that association of anti-TNF drug levels with clinical outcomes is also valid for perianal fistulae response.
There is scarce data from prospective studies regarding the efficacy of combination treatment on the fistula response. A retrospective study by Bouguen et al. demonstrated that ileocolonic disease, concomitant immunosuppressants, and duration of seton drainage, were factors associated with fistula closure. 3 In our study, concomitant immunomodulation was more prevalent in responders; however, the difference did not reach statistical significance, most probably due to the relatively small cohort size. In addition, utilization of setons was somewhat higher in non-responders in our study. However, this observation may indicate more active and complex fistulizing disease, as simple fistulae may heal without the need for seton placement. [16] On the other hand, complex fistulae require multidisciplinary management and almost always require seton drainage. [16] [17] [18] Our study has several limitations. This was a retrospective study with a relatively small cohort. We had to exclude patients with unavailable drug levels or insufficient clinical follow-up. An additional substantial limitation of the study stems from the clinical nature of the follow-up, with only a few patients having repeated imaging.
In conclusion, high induction IFX levels at Weeks 2 and 6 are independently associated with fistula response at both Weeks 14 and 30. If confirmed in a large-volume prospective study, our results may suggest the need to aim for early target IFX levels during induction in order to achieve an optimal response in CD patients with perianal fistulae.
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